Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration;Estudio de la actividad comparada de varias fluoroquinolonas frente a Pseudomonas aeruginosa mediante la determinación de la concentración preventiva de mutantes

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 10, 2006, Pages 603-607

  Sirvent, Elia ^a   Ruiz, Montserrat ^a   Rodríguez, Juan C ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Fluorquinolones; Mutant prevention concentration; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONCENTRATION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 33846414725     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095370     Document Type: Article

References (52)

1. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect. 2003;9:980-3.
2. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001; 33 Suppl 3:147-56.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th International supplement. CLSI documente M100-S15. Wayne: CLSI; 2005.
4. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother. 2004;53:252-7.
5. Pfaller MA, Hollis EJ, Sader HS. Molecular Biology. PFGE Analysis of chromosomal restriction fragment. Clinical Microbiology Procedures Handbook. 1992.P.10.5.c.1-10.c.11
6. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electroforesis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-9.
7. Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 mg) versus those of ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47: 3789-94.
8. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000;44:2600-3.
9. Debon R, Breilh D, Boselli E, Saux MC, Duflo F, Chassard D, et al. Pharmacokinetic parameters of ciprofloxacin (500 mg/5 ml) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. J Chemother. 2002;14:175-80.
10. Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother. 1998; 42:2235-9.
11. Owens RC Jr, Patel KB, Banevicius MA, Quintiliani R, Nightingale CH, Nicolau DP. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob-Agents-Chemother. 1997;41:1508-11.
12. Garrelts JC, Jost G, Kowalsky SF, Krol GJ, Lettieri JT. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob Agents Chemother. 1996;40: 1153-6.
13. Shah A, Liu MC, Vaughan D, Heller AH. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 ml or 500 mg/5 ml suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother. 1999;43 Suppl A:49-54.
14. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114-22.
15. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101-19.
16. Traunmuller F, Thalhammer-Scherrer R, Locker GJ, Losert H, Schmid R, Staudinger T, et al. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother. 2001;47:229-31.
17. Hansen E, Bucher M, Jakob W, Lemberger P, Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intens Care Med. 2001;27:371-5.
18. Chien SC, Wong FA, Fowler CL, Callery-D'Amico SV, Williams RR, Nayak R, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42:885-8.
19. Geerdes-Fenge HF, Wiedersich A, Wagner S, Lehr KH, Koeppe P, Lode H. Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrob Agents Chemother. 2000;44:3478-80.
20. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22:1216-25.
21. Capitano B, Mattoes HM, Shore E, O'Brien A, Braman S, Sutherland C, et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Cheat. 2004;125:965-73.
22. Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin.Clin Ther. 1999;21:513-22.
23. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998; 42:2060-5.
24. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy. 2000;20: 245-56.
25. Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34:898-903.
26. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999;44:835-8.
27. Naber CK, Steghafner M, Kinzig-Schippers M, Sauber C, Sorgel F, Stahlberg HJ, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 mg to volunteers. Antimicrob Agents Chemother. 2001;45:293-7.
28. Kays MB, Overholser BR, Lagvankar S, Goldman M, Sowinski KM. Effect of ensure on the oral bioavailability of gatifloxacin in healthy volunteers. Pharmacotherapy. 2005;25:1530-5.
29. Verho M, Malerczyk V, Dagrosa E, Korn A. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. Pharmatherapeutica. 1985;4:376-82.
30. Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enterai feeding in critically ill patients. Crit Care Med. 2003;31: 1347-52.
31. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995;39: 2635-40.
32. Honeybourne D, Banerjee D, Andrews J, Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2001;48:63-6.
33. Eboka CJ, Okor RS, Akerele JO, Aigbavboa SO. Kinetics of absorption and elimination of ofloxacin in humans after oral and rectal administrations. J Clin Pharm Ther. 1997;22:217-20.
34. Bardin C, Clavier M, Darchis JP, Chauvin M, Veyssier P, Farinotti R. Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections. Therapie. 1992;47:35-9.
35. Flor S, Beals B. The bioavailability of ofloxacin from several formulations. Curr Med Res Opin. 1991;12:282-6.
36. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004;48: 125-30.
37. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590-7.
38. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45: 3468-73.
39. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome at Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668-74.
40. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-83.
41. Hyatt JM, Schentag JJ. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect Control Hosp Epidemiol. 2000;21 Suppl 1:9-11.
42. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frecuency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251-3.
43. Prabhu RM, Elliott MA, Patel R. Apparent failure of moxifioxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clin Infect Dis. 2004;38:1043-5.
44. Nakano M, Yasuda M, Yokoi S, Takahashi Y, Ishihara S, Deguchi T. In vivo selection of Pseudomonas aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection. Urology. 2001;58:125-8.
45. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670-7.
46. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003;37:1643-8.
47. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI). Infection. 2003;31:208-15.
48. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745-51.
49. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001; 33:1859-64.
50. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112:275-85.
51. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2003;23:916-24.
52. Paladino JA, Sunderlin JL, Forrest A, Schentag JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2003;52: 457-63.